Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chengzhi Xie"'
Publikováno v:
Oncotarget
// Jianyun Zhao 1, 4, 5, * , Chengzhi Xie 2, 3, * , Holly Edwards 2, 3 , Guan Wang 1 , Jeffrey W. Taub 3, 4, 5 , Yubin Ge 1, 2, 3, 4 1 National Engineering Laboratory for AIDS Vaccine and Key Laboratory for Molecular Enzymology and Engineering, The M
Publikováno v:
Molecular Oncology. 9:409-421
Resistance to cytarabine and anthracycline-based chemotherapy is a major cause of treatment failure for acute myeloid leukemia (AML) patients. Overexpression of Bcl-2, Bcl-xL, and/or Mcl-1 has been associated with chemoresistance in AML cell lines an
Autor:
Chengzhi Xie, Jeffrey W. Taub, Yubin Ge, Liping Xu, Bailing Chen, Holly Edwards, Yi Liao, Lisa Polin, Hai Lin, Zhihui Qin, Xiaojia Niu
Synergistic-to-additive antileukemic interactions of piperlongumine (PL) and HDAC inhibitor (HDACi) SAHA (Vorinostat) provide a compelling rationale to construct PL-HDACi hybrids, such as 1-58, which recapitulated the synergism between the parental c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c4f20a50be2900c846d67e025ce108
https://europepmc.org/articles/PMC6878111/
https://europepmc.org/articles/PMC6878111/
Autor:
Jeffrey W. Taub, Chengzhi Xie, Steven Buck, Salvatore B. LoGrasso, Holly Edwards, Larry H. Matherly, Yubin Ge
Publikováno v:
Pediatric Blood & Cancer. 59:1245-1251
Background Acute myeloid leukemia (AML) remains a major therapeutic challenge in pediatric oncology even with intensified cytarabine (ara-C)-based chemotherapy. Therefore, new therapies are urgently needed to improve treatment outcome of this deadly
Autor:
Jun Ma, Shengyan Xiang, Chengzhi Xie, Jianyun Zhao, Zhihong J. Wang, Roland Chu, Jeffrey W. Taub, Xiaojia Niu, J. Timothy Caldwell, Yubin Ge, Xiaohong Zhang, Holly Edwards, Hai Lin, Guan Wang
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(17)
Purpose: To investigate the molecular mechanism underlying intrinsic resistance to ABT-199. Experimental Design: Western blots and real-time RT-PCR were used to determine levels of Mcl-1 after ABT-199 treatment alone or in combination with cytarabine
Autor:
Jeffrey W. Taub, Mark Stout, Holly Edwards, Qun Yu, Jeffrey E. Rubnitz, Chengzhi Xie, Hui Zhou, Larry H. Matherly, Xuelian Xu, Yubin Ge, Steven Buck
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(22)
Purpose: To determine the possibility of synergistic antileukemic activity and the underlying molecular mechanisms associated with cytarabine combined with valproic acid (VPA; a histone deacetylase inhibitor and a Food and Drug Administration–licen
Autor:
Hiroto Inaba, Chengzhi Xie, Yubin Ge, Holly Edwards, Jeffrey W. Taub, Christina D. Drenberg, Sharyn D. Baker, Steven Buck
Publikováno v:
Cancer Research. 72:2739-2739
Acute myeloid leukemia (AML) remains a challenging disease to treat. Resistance to anthracycline [e.g., daunorubicin (DNR)] and ara-C-based chemotherapy is a major cause of treatment failure in this disease. Therefore, new therapies are urgently need